Abbexa

Rainy day in Belfast today but fear not, Abbexa still have a few umbrellas! If you’re in Belfast, come and say hello to our team at the Microbiology Society Annual Conference. We’ll be at stand 12 until Thursday, April 16. #Microbio26 #Microbiology #Abbexa @MicrobioSoc

Get 15% off some of our top-selling CLIA Kits: · Human Thyroglobulin (TG) CLIA Kit · Human Angiopoietin 1 (ANG1) CLIA Kit · Mouse Tumor Protein (TCTP1) CLIA Kit and more! 🔗 Offer ends on the 31st of May: abbexa.com/products/elisa… #CLIAkit #ELISAkit

Get high quality antibodies with 15% off, including products from Abbexa’s top 100 bestsellers list: 🔬 Mucin-21 (MUC21) Antibody 🔬Defensin Alpha 5, Paneth Cell Specific (DEFA5) Antibody Explore all available products with 15% off: abbexa.com/products/elisa…

When it comes to BRCA1, understanding the tumour microenvironment is vital for the effectiveness of therapeutics. At Abbexa we’re here to support these discoveries. See more of our cancer research essentials at Abbexa.com

Known as a hereditary risk marker, BRCA1 safeguards our genome by promoting DNA repair, meaning that without this gene, tumour cells can grow more easily. Mutations in this gene are strongly associated with the development of breast cancer.

One highlight from our Top-100 range is the Human Aspartoacylase (ASPA) ELISA Kit (Catalogue No: abx519903). It’s now available at 15% off. Discover the full promotion on our website and see which other ELISA, CLIA, and antibodies are included: abbexa.com/products/elisa…

Get 15% Off Selected ELISA Kits, CLIA Kits, and Primary Antibodies: abbexa.com/products/elisa… Offer ends 31 May 2026. Stock up today and keep your research moving.

Curiosity drives scientific progress, and having specific, reliable tools helps researchers get clear, dependable results. With AACR on the horizon, we’re highlighting our range of cancer research essentials, featuring hundreds of cited products abbexa.com/products/essen…

As a result, a growing interest among researchers is the tumour microenvironment with a focus on SFRP2 What does the use of SFRP2 mean for the future direction of therapeutic strategies in TNBC? Find out in our latest article. abbexa.com/The-Emergence-…

Accounting for approximately 15% of breast cancer cases, Triple Negative Breast Cancer is one of the most difficult cancers to treat. This is due to the lack of hormonal and molecular markers targeted by modern therapies.

Abbexa will be exhibiting at the Microbiology Society Annual Conference 2026, taking place from 13–16 April at the ICC Belfast. Come and meet our team to see how we can support your work in microbiology. Our infamous grey felt bags and umbrellas will be there too! #Microbio26

Reliable insights depend on reliable tools. Abbexa offers a wide catalogue of specific, fully validated antibodies designed to support consistent, trustworthy results, including our Mucin 21 (MUC21) Antibody. Explore our catalogue: abbexa.com/products

MUC21 shows distinct expression in several tumour types, including lung adenocarcinoma, skin cancers, and brain tumours. This makes MUC21 a potential candidate for the diagnosis, treatment, and recovery outcomes, making it a key focus for ongoing oncology research.

The Mucin 21 (MUC21) Antibody continues to gain attention in cancer research, and a 2024 study highlights why: researchers suggest that MUC21 may be a potential new target for tumour treatment.

We were delighted to represent Abbexa at the Cambridge Biomedical Campus Careers Fair! It was great meeting so many talented people and discussing careers in life sciences. If you’d like to learn more about working at Abbexa, visit our careers page: abbexa.com/careers

At Abbexa, we’re here to make that journey more efficient. Our custom multiplex kits enable you to detect multiple antigens, saving both time and precious sample volume. As researchers know, it’s rarely just one biomarker that tells the whole story. abbexa.com/custom-multipl…

Increasingly, researchers are turning to Multiplex Immunofluorescence (mIF) and Multiplex Immunohistochemistry (IHC) to uncover how specific immune cells interact with tumour cells, helping to sharpen clinical prognosis and improve treatment predictions.

Understanding the complexity of the tumour microenvironment is essential for advancing cancer diagnostics and treatment.

Meanwhile, UNC13C has been identified as an independent prognostic indicator for liver cancer (HCC), meaning that this protein might be a prognostic biomarker and therapeutic target in HCC.

These proteins are recognised for their involvement in immune regulation and tumour biology. More specifically, UNC13D has a vital role in immune cell function response, meaning it is used to prompt immune cells to react to cancerous cells, making it a key point in immunology

Recent research highlights the pivotal roles that members of the UNC13 family have been observed to play in various types of diseases, including different types of cancer.